Valuation: HOOA PHARPAR

Market Cap 1.14Cr 1Cr 92.33L 85.27L 1.62Cr 109.14Cr 1.65Cr 11Cr 4.33Cr 54Cr 4.3Cr 4.2Cr 184.84Cr P/E 2023
-0.94x
P/E 2024 -0.58x
Enterprise Value -2.74Cr -2.39Cr -2.21Cr -2.04Cr -3.87Cr -261Cr -3.93Cr -26Cr -10Cr -128.58Cr -10Cr -10Cr -442.01Cr EV / Sales 2023
-0.45x
EV / Sales 2024 -0.31x
Free-Float
65.98%
Yield 2023 *
-
Yield 2024 -
1 day+0.88%
3 months+0.88%
6 months+26.37%
Current year+28.78%
Current year 0.88
Extreme 0.884
1.2
1 year 0.81
Extreme 0.811
1.2
3 years 0.72
Extreme 0.721
11.3
5 years 0.72
Extreme 0.721
86.9
10 years 0.72
Extreme 0.721
200
Manager TitleAgeSince
Chief Executive Officer 63 22/07/2024
Director of Finance/CFO 64 22/07/2024
Chief Tech/Sci/R&D Officer 48 01/01/2019
Director TitleAgeSince
Chairman 60 30/08/2024
Director/Board Member 53 25/04/2019
Director/Board Member 63 01/01/2023
Date Insider Type Main position Quantity % Market Cap.
19/25/19Sell

Chief Executive Officer

25,172 0.2607%
22/25/22Sell

Chief Executive Officer

29,176 0.3022%
22/25/22Sell

Chief Financial Officer

13,609 0.1410%
Change 5-day change 1-year change 3-year change Capi.($)
+0.88%-.--%-3.36%-85.98% 1.48Cr
+1.84%-0.66%+59.82%+92.96% 5.49TCr
-4.14%-8.06%+58.96%+118.67% 5.46TCr
-2.24%+3.59%+17.75%+477.47% 2.51TCr
-1.60%-6.21%-18.96%-15.21% 2.31TCr
+2.43%+1.06%+42.44%-1.27% 1.99TCr
-3.19%0.00%+35.60%-26.98% 1.75TCr
-6.84%+2.18%+195.12%+357.18% 1.65TCr
+8.74%+3.51%+51.91%+726.40% 1.57TCr
-1.05%+1.16%+25.95%+194.27% 1.42TCr
Average -0.52%-0.50%+46.52%+183.75% 2.42TCr
Weighted average by Cap. -0.89%-1.45%+51.26%+177.12%

Financials

2023 2024
Net sales 2.01Cr 1.76Cr 1.62Cr 1.5Cr 2.85Cr 191.98Cr 2.89Cr 19Cr 7.62Cr 95Cr 7.56Cr 7.39Cr 325.13Cr 4.39Cr 3.84Cr 3.55Cr 3.27Cr 6.21Cr 419.13Cr 6.32Cr 42Cr 17Cr 206.48Cr 17Cr 16Cr 709.82Cr
Net income -8.16Cr -7.14Cr -6.58Cr -6.08Cr -12Cr -778.06Cr -12Cr -79Cr -31Cr -383.3Cr -31Cr -30Cr -1.32TCr -4.35Cr -3.81Cr -3.51Cr -3.24Cr -6.15Cr -414.91Cr -6.25Cr -42Cr -16Cr -204.4Cr -16Cr -16Cr -702.67Cr
Net Debt -11Cr -9.67Cr -8.92Cr -8.24Cr -16Cr -1.05TCr -16Cr -106.56Cr -42Cr -519.35Cr -42Cr -41Cr -1.79TCr -3.88Cr -3.39Cr -3.13Cr -2.89Cr -5.49Cr -370.14Cr -5.58Cr -37Cr -15Cr -182.34Cr -15Cr -14Cr -626.85Cr
Logo HOOA PHARPAR
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that is designed to target and amplify T cell and immune responses to fight diseases. The Company's replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. The Company is also engaged in the assessment of strategic alternatives and the development of infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are developed in a partnership with Gilead Sciences Inc.
Employees
85
  1. Stock Market
  2. Stocks
  3. HOOK Stock